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An interim report by Professor John 
Strang, chair of the expert group
Background 
In August 2010, the NTA – on behalf of the 
Department of Health – asked me to chair a group to 
provide guidance to the drug treatment field on the 
proper use of medications to aid recovery and on how 
the care for those in need of effective and evidence-
based drug treatment is more fully orientated to 
optimise recovery. This work would also address the 
critical observation, subsequently highlighted in the 
2010 Drug Strategy1, that “for too many people 
currently on a substitute prescription, what should be 
the first step on the journey to recovery risks ending 
there.” As an example of the recovery orientation, 
the strategy expected that “all those on a substitute 
prescription engage in recovery activities”.
The group’s task would be to provide guidance to 
clinicians about the more effective provision of 
recovery-orientated opioid substitution and other drug 
treatments as part of broader personalised recovery 
plans. For some individuals with heroin addiction, the 
best treatment may include substitute medication, while 
for others this may be inappropriate or unnecessary. In 
all instances, the objective is to enable individuals to 
achieve their fullest personal recovery. The expert group 
would develop clinical protocols to guide clinicians and 
agencies so they can help individuals make progress 
towards this objective, improve support for long-term 
recovery, and avoid unplanned drift into open-ended 
maintenance prescribing.
This project was a central plank of the NTA’s business 
plan for 2010-112.
I selected a wide group of experts from across the 
country. Many of these were experienced clinicians 
whose working practice includes prescribing 
medications for addiction treatments in primary and 
secondary care settings. Experts also came from a 
range of other clinical and rehabilitative settings, often 
bringing a breadth of knowledge and experience of 
recovery-orientated programmes. The group included 
colleagues who have voiced criticisms of the current 
system, and others who brought experience of driving 
improvements in the recovery focus of addiction 
treatments.
The group was joined by observers from government 
departments and the NTA, which also provided its 
secretariat. We also have the benefit of a number of 
experts from across the world who have kindly agreed 
to provide advice by correspondence.
The group’s agreed terms of reference are appended.
Since the group was convened in October 2010 we 
have met six times and covered much ground. Further 
work has taken place outside the full meetings, 
including that of sub-groups (reported below). We 
still have more to do and we expect to produce a 
substantial product which reports conclusions and 
recommendations early next year. In the meantime, 
I am able to provide some early observations about 
where we have found common ground, how 
treatment services and systems can immediately 
improve the treatment they offer to patients*, and a 
vision for recovery-orientated drug treatment.
*I have used the term ‘patient’ throughout, in part because of the clinician 
orientation of this document, but we are aware others may prefer different terms. 
Whatever the terminology and framework, we are looking to ensure an orientation 




The group noted the remarkably strong body of 
research evidence for the effectiveness of opioid 
substitution treatment (OST), albeit mostly from 
other countries. When delivered correctly to the right 
individuals at the right time, OST retains patients in 
treatment, supports improvements in health and 
social functioning, reduces crime and illicit drug 
use, prevents the spread of blood-borne viruses and 
protects against overdose.
We need to hold on to what is good, and use it as 
a platform from which to achieve more. We have 
listened and heard evidence from drug users and 
colleagues around the country that, too often, people 
with addiction problems could be better supported 
in their recovery, and that there could be greater 
ambition for and focus on their potential to make 
further progress.
There has been a growing recognition of imbalance 
within the system over the last few years. The re-
examination of drug strategy following the election 
of the coalition government in May 2010 was the 
catalyst for the review we are currently undertaking.
The group also noted the diversity and complexity of 
both drug misuse and the needs of those who use 
drugs. It has rarely been the case that a problem with 
a single drug requires a single, simple solution; many 
people in need of treatment have complex physical, 
mental health and social problems requiring complex 
interventions.
The drive in recent years to reduce waiting lists 
and retain people in treatment has generally been 
successful with the result that much larger numbers of 
patients with addiction problems now enter treatment. 
This has undoubtedly been accompanied by significant 
benefits for many patients and the communities in 
which they live. 
However, the desire of clinicians to secure these 
benefits has led, in some instances, to over-reliance 
on medication and patients being allowed to drift into 
long-term maintenance. As a consequence, insufficient 
attention may have been paid to reviewing the actual 
benefits gained, reconsidering alternative methods 
to maximise the prospect of personal recovery, and 
adjusting treatments so that greater recovery could be 
achieved.
The prescribing of any medication (and perhaps 
especially of OST) must not be allowed to become 
detached and delivered in isolation from other crucial 
components of effective treatment. Other elements 
of overall care need also to be considered, including 
individual recovery care planning, psychosocial 
interventions and integration with mutual aid and peer 
support. All of these, in different combinations with 
different patients, and adjusted over time, can and do 
support recovery.
Services have grown significantly during the sector’s 
rapid expansion, which has been a time of greater 
reliance on medication. Staff working in these services 
may need additional training and support to gain the 
competences to improve the quality of regular review 
and restructuring of personalised care to support 
recovery.
We already have considerable experience and 
expertise within the UK available to us, and we also 
have good international links so we can learn from 
the best practitioners and researchers in the world. 
Consequently we are in a strong position to deliver 
any changes that, as a result of our review, we 
consider necessary.
Existing guidancE, and thE ExtEnsivE 
EvidEncE on which it is BasEd, alrEady 
dEscriBEs much of what is BEst practicE
In its initial deliberations the group reconsidered some 
of the key elements of effective drug treatment and 
concluded that to a large extent they were already 
described in existing clinical and other guidance, 
although not always followed in practice. The 
previously identified extensive research evidence base 
had also been further strengthened.
A comprehensive assessment of need is an 
essential early (and ongoing) step in the planning 
of personalised treatment and it should also be an 
integral part of the therapeutic process. Assessment 
should not be a process that happens to someone but 
one in which they are actively involved, to the fullest 
appropriate degree, and about which they develop 
their own understanding of their situation alongside 
the understanding provided by the clinician.
The recovery care plan that results from this 
assessment, and subsequent revisions when progress is 
reviewed, must be developed collaboratively so that it 
is personally relevant and ‘owned’ by the patient. This 
will increase the likelihood that they commit to, and 
are motivated by, a personal recovery care plan that is 
meaningful to them.
The construction of a recovery care plan should be built 
around the individual patient. Pre-existing packages 
of care may be used, but they must be carefully and 
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deliberately chosen to support the individually relevant 
personalised treatment that is essential to ensure an 
individual response based on need.
The provision of a prescription alone should not be 
considered to constitute the totality of treatment. 
Previous guidance3 has made it abundantly clear that 
better results can generally be achieved by the proper 
incorporation of psychosocial interventions within a 
comprehensive OST programme. However it needs to 
be noted that even OST with minimal psychological 
input can reduce injecting and drug-related deaths.
In our opinion, while the gains from the medication 
component of treatment can be significant, there 
would be benefit from incorporating more of these 
non-medication elements of treatment and from 
aiming for higher achievement from such treatments. 
The competent provision of the medication element of 
the treatment – and tailoring it to the individual – may 
be important, but it is still only the medication element.
Medication can valuably support individuals to 
make changes to harmful behaviour, just as nicotine 
replacement treatments can help individuals to quit 
their previous smoking; but in such cases, active 
commitment and effort is required from the individual 
in order to maximise the impact of the medication.
Regular reviews of progress enable the clinician and 
patient to assess continuing and changed need, and 
appropriate responses. The Treatment Outcomes 
Profile (TOP) has been specifically developed and 
validated4 for use in reviewing progress, and has been 
widely adopted on a routine regular basis by many 
treatment agencies. 
We have considered criticisms of the TOP as a tool 
and of its intrusion into clinical practice. There may be 
room for improvement – and the NTA is addressing 
this – but it is essential that a culture of regular use 
of common validated measures becomes part of 
our clinical practice. This includes tracking progress 
as evidenced by change over time, and ensuring 
widespread use of the same (or directly comparable) 
measures across clinicians and services.
Repeated reviews should result not only in a 
personalised assessment but also the optimised 
treatment for the individual. This should include – but 
certainly not be limited to – attention to elements 
of the medication component of treatment. If an 
individual is deriving little or no benefit from an 
intervention, then it should be modified and tailored 
in partnership with the patient so that the provision of 
the treatment delivers identified and valued benefit.
thE total packagE may appEar complEx 
and will follow, But this is what can 
alrEady BE donE
The total package for delivering recovery-orientated 
drug treatment is likely, in its full description, to be 
complex. It may take time for some treatment services 
and systems to fully re-orientate to achieve the best 
balance between reduction of negatives and accrual 
of positives. Our full report, described on page 7, will 
cover this balance in more detail.
In the meantime, there are some immediate steps 
that can be taken to improve the recovery orientation 
of treatments that include prescribing, and to ensure 
there is appropriate support for patients to achieve the 
best secure gains:
1. Conduct an audit of the balance in your service  
 between overcoming dependence and reducing  
 harm to ensure that both objectives properly  
 co-exist; and that individual clinicians understand  
 and apply a personalised assessment for each  
 patient, repeat it at regular intervals, and on the  
 basis of its findings re-examine and adjust the  
 treatment plan jointly with the patient
2. Review all your patients to ensure they have   
 achieved abstinence from their identified problem  
 drug(s) or are working actively to achieve   
 abstinence. Patients should also be offered the  
 opportunity to come off medication after   
 appropriate careful planning, when they are ready
3. Consider whether to change the current balance  
 between promoting overcoming of dependence  
 and promoting reduction of harms, with the aim of  
 actively encouraging more patients to take   
 opportunities to recover. Although no clinician 
 should take unwarranted risk, neither should they  
 protect patients to the extent that they are not  
 encouraged and enabled to get better. This must  
 always be undertaken in a way that supports each  
 patient to make an informed choice that is relevant  
 to their personal situation and is based on an  
 accurate description of the available options
4. Ensure exits from treatment are visible to patients  
 from the minute they walk through the door of  
 your service. This means giving them enough  
 information to understand what might comprise a  
 treatment journey, even if their eventual exit   
 appears to some way off. And make visible those  
 people who have successfully exited by explicitly  
 linking your service to a recovery community, or  
 employing ex-service users or using them in a  
 volunteer capacity as recovery mentors and coaches
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5. If agonist or antagonist medications are being  
 prescribed, then review, jointly with each patient  
 and with input, as appropriate, from relevant third  
 parties, the extent of benefit still being obtained
6. For patients who have achieved stability while on  
 medication and who choose to reduce and/or stop  
 the medication, ensure that support mechanisms  
 are in place to support this transition, and also  
 ensure that rapid re-capture avenues are in place  
 and are understood and acceptable to the patient,  
 in the event of failure of the transition
7. Check that all treatment is optimised so patients  
 are receiving the range and intensity of  
 interventions that will give them the best chance of  
 recovery. This may include optimised doses of  
 appropriate medications; the reintroduction,   
 reduction or dropping of supervised consumption  
 as appropriate; active keyworking, including case  
 management and psychosocial interventions that  
 keyworkers are competent to provide; access to  
 other psychosocial interventions requiring   
 additional competences; etc. As a first step, audit  
 the availability of key NICE-recommended   
 psychosocial interventions5, using the audit tool in  
 the NTA/BPS Toolkit6
8. Strengthen or develop patients’ social networks,  
 involving families where appropriate and   
 facilitating access to mutual aid by, for example,  
 providing information, transport, or premises for  
 meetings, and by bringing local recovery   
 champions into the service to meet patients
9. Establish opportunities to accrue ‘social capital’  
 via work experience placements or employment,  
 training opportunities, volunteer work, etc
10. Ensure all keyworkers are trained and supervised to  
 deliver psychosocial interventions of a type and  
 intensity appropriate to their competence. Effective  
 keyworking entails not only recovery care planning,  
 case management, advocacy and risk management,  
 but also collaborative interventions designed to  
 raise the insight and awareness of patients and help  
 them plan and build a new life. This will often  
 involve attention to employment and housing
11. Review the quality of your service’s recovery care  
 planning and take steps to improve it, wherever  
 possible. Recovery care plans should be personally  
 meaningful documents, developed over a period of  
 comprehensive assessment, and reviewed and  
 adapted regularly, so that they are important to  
 and owned by the patient
12. Ensure your service works with local housing and  
 employment services, and in partnership with  
 commissioners, to ensure there is supported and  
 integrated access to relevant provision.
wE will nEEd a rEnEwEd Emphasis on 
improving pEoplE’s rEcovEry
The new agenda is about more than business as usual 
(or even business as it should have been). The new 
emphasis on recovery will often best be addressed by 
recourse to constructing personalised recovery care 
plans which include reintegration and peer support.
While not losing the benefits from reduction of 
the harms associated with drug use and addiction, 
the new emphasis will probably also require more 
prominent attention to efforts to obtain the positives, 
by embracing a more proactive and aspirational 
approach, identifying strengths and increasing 
ambition to make important behavioural changes.
For the future, we envisage a much stronger and 
more explicit focus on supporting the individual to 
reintegrate within mainstream society. Not only does 
this bring advantages and responsibilities, but it is 
also as ‘therapeutic’ in its own right, with discernible 
positives for the individual themselves as well as for 
society at large. Drug treatment services, working 
in conjunction with individual patients, will need to 
establish mechanisms of joint working with the wide 
range of services that can support someone to get a 
job, housing, healthcare, etc.
We are exploring the extent to which a greater 
emphasis on peer-led recovery (e.g. greater 
incorporation of, and reliance on, peer-support and 
mutual aid) may be beneficial, at least for some 
patients and at some particular stages of treatment 
and rehabilitation. This may require clinicians to 
recognise the strengths brought by our patients and 
their peers to enable one another to achieve and 
sustain recovery, and to give them greater control over 
how and where treatment and recovery occur. 
our work has BEgun to addrEss four 
kEy arEas, and markEd two morE as 
nEEding futurE attEntion
The group identified gaps or a lack of consensus in 
four main areas, one of which has already been the 
subject of a formal sub-group reporting to the main 
group, and three of which have been the subject of 
attention from subsets of the main group.
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The area immediately delegated to a sub-group was 
around understanding the proportion of patients who 
might be expected to rapidly recover with no or limited 
substitute prescribing and what proportion will need 
long-term care, including substitute prescribing. A sub-
group chaired by Dr David Best was asked to develop 
thinking on “patient placement criteria” (see below). 
The sub-group’s terms of reference are appended.
The next three areas settled on by the main RODT 
group as needing further attention were:
A. Understanding the dimensions of recovery and 
how these fit into a conceptual framework 
As the first step on the road to recovery, treatment 
needs to focus not only on preventing immediate and 
longer-term harm but also on helping patients to build 
the resources they will need to sustain that recovery: 
‘recovery capital’. The 2010 Drug Strategy gives us 
a framework for recovery and the work in this first 
area focussed on the implications of that framework 
for prescribing practice. Sometimes clinicians may 
be too ready to accept the reduction of negatives 
which can occur rapidly with prescribing interventions 
as sufficient impact of the treatment, and they may 
consequently fail to work with their patient on the 
accrual of positives, with the involvement in treatment 
acting as a platform for increasing someone’s social, 
physical, human and cultural recovery capital. 
B. Determining how progress in treatment and the 
accumulation of ‘positive capital’ can be measured 
Monitoring the benefits from, and progress of, 
treatment is an essential element of good clinical 
practice. The work in this second area has been to 
consider how recovery capital and its accumulation 
can best be measured in treatment. We are 
considering the potential contribution of various 
possible measures of such recovery capital. We are 
mindful of the wide current use of the Treatment 
Outcomes Profile (TOP) which has been central to the 
NTA’s recent work in this area, but it has been agreed 
that the measurement of recovery (what we have 
taken to calling ‘recoverometry’) will require greater 
attention to the dimensions of recovery identified in 
the first area of work.
C. Developing an understanding of how 
interventions can be layered and sequenced to 
support a personally-relevant and evolving journey 
of treatment and recovery.
Bringing the previous two areas together, the third 
area of work is then concerned with how treatment 
interventions and the systems in which they are 
provided can be better sequenced and/or layered: 
an analysis of who gets what when, and how it is 
best delivered. We are exploring how, through a 
closer definition of the components of treatment and 
organising them into varying intensities and phases, 
it may be possible for there to be more effective and 
more efficient deployment of available resources 
in such a way as to maximise overall individual and 
societal benefit.
The two areas requiring future attention are:
 • How to optimise opioid substitution therapy, which  
 may involve different intensities and need targeted  
 phases of treatment
 • The potential wider future use of a range of   
 medications (existing and in development, and also  
 considering new emerging technologies) in a range  
 of treatment and recovery settings.
Patient placement criteria
The sub-group commissioned to examine patient 
placement criteria developed in two areas:
1. Segmentation locality assessment
Developing models for dividing up treatment and 
recovery populations to allow for an understanding 
of differential rates of recovery probability
2. Treatment and recovery indicators
Developing a set of indicators that can be used by 
keyworkers at assessment and review to identify 
treatments and specific interventions from which 
clients may be most likely to benefit.
The PPC sub-group is still busily engaged in 
its work. It heard the initial outcomes of the 
Segmentation Locality Assessment work in April 
and plans to follow this with an initial tool for 
testing the treatment and recovery indicators. 
All of this work will first come to the full RODT 
group for consideration and incorporation (as 
appropriate) and, while it is ongoing, forms no 
further part of this interim report.
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a vision for thE futurE
Our vision for the future is a system:
 • In which the valuable role of prescribing continues  
 to be recognised, though it is not an end in itself  
 but a component of a phased, integrated package  
 of treatment that minimises risk while being   
 ambitious for each individual patient’s recovery
 • That develops and supports staff to adopt   
 recovery-orientated practice and in which they are  
 trained to deliver evidence-based psychosocial  
 interventions alongside medical interventions
 • In which everyone entering treatment is enabled  
 to see and understand the range of treatment and  
 recovery options open to them, the trajectories of  
 the journey on which they are embarked, and the  
 possible destinations of that journey
 • That seeks to maximise what individuals can   
 achieve, with a clear overall sense of movement and  
 progress for patients, even during those periods  
 when they are appropriately allowed to settle and  
 stabilise
 • That recognises the real achievement of preventing  
 the deterioration that would otherwise have   
 occurred to more severely damaged patients
 • That closely involves families and carers in patients’  
 treatment, and supports them in their own right
 • That has close links to its community, that works  
 alongside other systems to facilitate access to a  
 broad range of reintegration and recovery support
 • In which there are well-defined roles for current  
 and future medications in stabilising, maintaining  
 and detoxifying patients, and preventing relapse in  
 different settings.
thE group’s full rEport
Our full report later this year is expected to cover:
 • A summary of the key evidence for medication  
 factors important in promoting recovery 
 • A conceptual framework of recovery which   
 specifically examines how benefits of medication  
 can be harnessed to best effect
 • Guidance on measuring treatment benefit to   
 support progress
 • A description of how to optimise both opioid   
 substitution therapy and also the accompanying  
 psychological and psychosocial treatments, which,  
 for both, may involve different intensities and need  
 targeted phases of treatment
 • Strategies to encourage greater constructive use of  
 peer role-models and peer support
 • Guidance on how it might be possible to open up  
 new opportunities for patients making progress in  
 their personal recovery to be supported further with  
 employment opportunities and other ways of   
 accruing ‘social capital’
 • The potential for the use of a range of medications  
 in treatment and recovery settings.
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appEndix a  




During 2010-11 the NTA will work to reposition the 
treatment system to focus on safe and sustained 
recovery, and to demonstrate transparent outcomes, 
while consistently providing more for less. As part 
of this work the NTA is convening an expert group 
of clinicians and other interested parties to develop 
clinical guidance and tools in two closely related areas.
Firstly, the NTA is committed to exploring the 
principle that open-ended substitute prescribing in 
the community should only be used in exceptional 
circumstances and only on the basis of a rigorous, 
multidisciplinary review of a patient’s ongoing needs. 
The objective is to make the system more dynamic. 
We do not want to allow service users to drift into 
long-term maintenance prescribing without effort 
being made to promote beneficial change in their 
lives. Sound, evidence-based clinical judgement 
endorsed by clinical governance will be able to identify 
cases where the approach would not be appropriate, 
but the intent is to see a fundamental shift in 
the balance of treatment for opiate dependence, 
away from the unreviewed provision of long-term 
maintenance towards supporting individuals to 
overcome dependence and to recover fully.
The expert group will develop a clinical consensus and 
resultant protocols that focus practitioners and clients 
on supporting long-term recovery as the desired 
outcome of treatment and prevent unplanned drift 
into long-term maintenance.
Secondly, we wish to develop patient placement 
criteria to maximise access to recovery-focused 
pathways, ensure a consistent and transparent 
approach to the commissioning of community and 
residential rehabilitation, and achieve a cost-effective 
balance between different types of treatment. This 
will be based on a consensus on which individual 
drug users would benefit most from which treatment 
service models. This would distinguish between 
those requiring long-term treatment and those who 
can safely and quickly overcome their dependence 
and achieve long-term recovery. The expert group 
will advise on the development of a model to match 
individual clinical need as closely as possible to the 
location, intensity and duration of the treatment that 
is most likely to be effective at promoting recovery 
including indicating those who are likely to benefit 
from residential treatment.
These tasks, and the expert group’s deliberations, are 
expected to feed into the NTA’s development of an 
explicit, recovery-orientated vision for the treatment 
system to replace the current framework, Models 
of Care for Treatment of Adult Drug Misusers, last 
updated in 2006. The document and accompanying 
implementation will facilitate the transformation 
of local treatment systems to enshrine that greater 
ambition, and ensure that achieving sustained recovery 
from addiction is the basis of all local commissioning 
and service delivery in prison and community settings.
Proposed work
The proposal is therefore that an expert working 
group should:
Develop, for and with the National Treatment 
Agency, clinical consensus and appropriate clinical 
protocols for substitute prescribing, and a model for 
the segmentation of the treatment population and 
suitable treatment placement indicators, both in the 
context of the developing recovery framework. 
It is likely that sub-groups may be needed to work on 
specific aspects of this wide-ranging task.
Status
The process of development by a respected expert 
group, with NTA and Department of Health support, 
will ensure the protocols and models are accepted as an 
important guide to best practice by the drug misuse 
treatment field and relevant professional bodies.
Coverage
The work relates to England only.
composition
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Professor John Strang (chair)
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Dr Alison Battersby – Psychiatrist, Plymouth
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Timetable 
It is proposed that the initial meeting of the expert 
group will take place in September 2010; that the 
subsequent meeting schedule will be determined by 
the work plan of the group, and that sub groups may 
meet more frequently. Meetings will usually be a half 
or full day and mostly held in London.
The final publications are expected in 2011-12, with:
 • An interim report on options for clinical protocols for  
 substitute prescribing planned for quarter 4 2010-11
 • National consultation on treatment placement  
 indicators scheduled for quarter 3 2010-11. Piloting  
 of the approach in selected parts of the country to  
 refine their effectiveness is scheduled for quarter 4  
 2010-11.
Outputs
 • The publication of clinical protocols for substitute  
 prescribing 
 • A model for segmentation of the treatment   




The expert group will be serviced and supported by 
the NTA, which will also fund meeting costs including 
travel costs for working group members.
Working group members will be able to claim hotel 
expenses for one night if necessary/appropriate. 
Expenses will be reimbursed on production of 
appropriate receipts and completed claim forms, 
according to NTA financial procedures.
appEndix B  
thE ppc suB-group tErms of rEfErEncE
nb. These terms of reference should be read with 




The NTA wishes to develop patient placement 
criteria to maximise access to abstinence-focused 
pathways, ensure a consistent and transparent 
approach to commissioning community and residential 
rehabilitation, and achieve a cost-effective balance 
between different types of treatment. This will be 
based on a consensus on which drug users would 
benefit most from which service models and recovery-
oriented pathways. This would distinguish between 
those requiring long-term treatment and those who 
could be safely and quickly moved to abstinence, and 
indicate those who are likely to benefit from residential 
treatment. The expert sub-group will advise on the 
development of a model to match individual clinical 
need as closely as possible to the location, intensity 
and duration of the treatment that is most likely to 
effectively promote recovery.
This is a sub-group of the RODT expert group, whose 
aim is to: 
“Develop, for and with the National Treatment 
Agency, clinical consensus and appropriate clinical 
protocols for substitute prescribing, and a model for 
the segmentation of the treatment population and 
suitable treatment placement indicators, both in the 
context of the developing recovery framework.”
The chair of the sub-group, David Best, will report 
back to the RODT group and will act as the link 
between the groups.
Proposed work
The proposal is that an expert sub-group should: 
Develop, for and with the National Treatment Agency, 
a model for the segmentation of the treatment 
population and the ‘at-need’ group not currently 
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engaged in treatment, in terms of their likely recovery 
pathways and journeys. This will prepare the way for 
matching to suitable treatment placement indicators, 
in the context of the developing recovery framework. 
Overall, the aims of the group are to agree a process 
for meaningful segmentation and to utilise this as 
a way of identifying matching criteria for treatment 
journeys and ongoing recovery pathways.
The work of the group will be to focus on initial 
assessment and the decision-making at different 
stages of recovery journeys, and will examine wider 
needs, including populations whose needs may be 
met without recourse to formal treatment.
Status
The process of development by a respected expert 
group, with NTA and Department of Health support, 
will ensure the protocols and models are accepted as an 
important guide to best practice by the drug misuse 
treatment field and relevant professional bodies.
Coverage
The work relates to England only.
composition
Membership 
Members will primarlily be drawn from the main RODT 
expert group but supplemented by the co-option of 
other key individuals.
RODT
Dr David Best (chair) – University of the West of 
Scotland
Jayne Bridge – Mersey Care NHS Trust
Dr Ed Day – University of Birmingham
Vivienne Evans – Adfam
Jason Gough – Service user voice
Kate Hall – Greater Manchester West
Linda Harris – Wakefield & RCGP
Tim Leighton – Action on Addiction
Peter McDermott – The Alliance
Co-opted
Nichola Adamson – Worcestershire DAAT
Karen Biggs – Phoenix Futures 
Wendy Dawson – The Ley Community
Tom Kirkwood – Trust the Process
Dave Knight – RCN
Dr David McCartney – LEAP
PPC Project Team
Colin Bradbury – NTA
Pete Burkinshaw – Skills and Development Manager
Alison Keating – NTA regional manager
Dr Michael Kelleher – NTA & SLAM
Dr John Marsden – NTA & IoP
Christopher Whiteley – NTA and East London NHS 
Trust
Observers/secretariat
Department of Health Substance Misuse team –  
Dr Mark Prunty, Amy Edens










Members will be required to declare any potentially 
conflicting interests in line with established DH policy 
and procedures.
Timetable 
The initial meeting of the main expert group will take 
place in December 2010, when consideration will be 
given to the frequency and timings of meetings of the 
sub group.
Outputs
 • An outline of segmentation methods and categories  
 for drug users in and out of treatment 
 • A model for segmentation of the treatment   




The sub-group will be serviced and supported by the 
NTA, which will also fund meeting costs including 
travel costs (if needed) for members.
Working group members will be able to claim hotel 
expenses for one night if necessary/appropriate. 
Expenses will be reimbursed on production of 
appropriate receipts and completed claim forms, 
according to NTA financial procedures.
